Other Assets, Noncurrent in USD of Rein Therapeutics, Inc. from Q4 2016 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of noncurrent assets classified as other.
Summary
Rein Therapeutics, Inc. quarterly Other Assets, Noncurrent history and change rate from Q4 2016 to Q3 2025.
  • Rein Therapeutics, Inc. Other Assets, Noncurrent for the quarter ending September 30, 2025 was $2K, unchanged year-over-year.
Other Assets, Noncurrent, Quarterly (USD)
Other Assets, Noncurrent, YoY Quarterly Change (%)

Rein Therapeutics, Inc. Quarterly Other Assets, Noncurrent (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $2K $0 0% Sep 30, 2025 10-Q 2025-11-14
Q2 2025 $2.35M +$1.64M +231% Jun 30, 2025 10-Q 2025-08-14
Q1 2025 $766K -$126K -14.1% Mar 31, 2025 10-Q 2025-05-15
Q4 2024 $2K -$2.19M -99.9% Dec 31, 2024 10-Q 2025-11-14
Q3 2024 $2K Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $709K Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $892K Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $2.19M +$2.17M +9038% Dec 31, 2023 10-K 2025-04-07
Q4 2022 $24K $0 0% Dec 31, 2022 10-K 2024-04-15
Q3 2022 $24K $0 0% Sep 30, 2022 10-Q 2022-11-01
Q2 2022 $24K $0 0% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $24K +$3K +14.3% Mar 31, 2022 10-Q 2022-05-05
Q4 2021 $24K Dec 31, 2021 10-K 2023-03-20
Q3 2021 $24K Sep 30, 2021 10-Q 2021-11-12
Q2 2021 $24K Jun 30, 2021 10-Q 2021-08-11
Q1 2021 $21K Mar 31, 2021 10-Q 2021-05-11
Q3 2019 $302K -$378K -55.6% Sep 30, 2019 10-Q 2019-11-07
Q2 2019 $302K -$378K -55.6% Jun 30, 2019 10-Q 2019-08-06
Q1 2019 $501K -$182K -26.6% Mar 31, 2019 10-Q 2019-05-08
Q4 2018 $679K -$15K -2.16% Dec 31, 2018 10-K 2020-03-30
Q3 2018 $680K -$128K -15.8% Sep 30, 2018 10-Q 2018-11-07
Q2 2018 $680K -$102K -13% Jun 30, 2018 10-Q 2018-08-07
Q1 2018 $683K Mar 31, 2018 10-Q 2018-05-09
Q4 2017 $694K -$84K -10.8% Dec 31, 2017 10-K 2019-03-29
Q3 2017 $808K Sep 30, 2017 10-Q 2017-11-09
Q2 2017 $782K Jun 30, 2017 10-Q 2017-08-10
Q4 2016 $778K Dec 31, 2016 10-K 2018-04-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.